Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Journal for ImmunoTherapy of CancerOpen Access

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

View Full Paper
Ask AI
Bookmark
Share

Authors

XHX HuSBShoiab BukhariCTCarly Tymm

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e7632bb6db6435876d8a51https://doi.org/10.1136/jitc-2023-008482
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy2019 · 493 citations
  2. 2The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)2020 · 83 citations
  3. 3A novel mouse model for checkpoint inhibitor-induced adverse events2021 · 62 citations
  4. 4Immunohistochemistry of Immune Cells and Cells Bound to in vivo Administered Antibodies in Liver, Lung, Pancreas, and Colon of B6/lpr Mice2022 · 3 citations